Argenx to acquire Forte Biosciences for $2.2bn in autoimmune push

Argenx (ARGX) has agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion, adding the experimental autoimmune therapy FB102 to its portfolio.

The Belgian-Dutch immunology company will pay $77 a share in cash for the US drug developer, securing rights to a first-in-class anti-CD122 antibody that has demonstrated early promise in treating vitiligo and celiac disease.